Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- FLUO.ST
- Price
- 35.40
- Stock movement up
- +0.50 (1.43%)
- Company name
- Fluoguide AS
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 578.77M
- Ent value
- 563.74M
- Price/Sales
- 10153.78
- Price/Book
- 10.61
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 14.16
- PEG
- -
- EPS growth
- 10.03%
- 1 year return (CAGR)
- -22.11%
- 3 year return (CAGR)
- -21.07%
- 5 year return (CAGR)
- -24.23%
- 10 year return (CAGR)
- -
Last updated: 2026-03-09
DIVIDENDS
FLUO.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 10153.78 |
| Price to Book | 10.61 |
| EV to Sales | 9890.12 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 16.35M |
| EPS (TTM) | -2.64 |
| FCF per share (TTM) | -2.73 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 57.00K |
| Gross profit (TTM) | -79.60K |
| Operating income (TTM) | -39.88M |
| Net income (TTM) | -39.62M |
| EPS (TTM) | -2.64 |
| EPS (1y forward) | 2.50 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -139.65% |
| Operating margin (TTM) | -69959.64% |
| Profit margin (TTM) | -69500.20% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 48.81M |
| Net receivables | 5.93M |
| Total current assets | 86.79M |
| Goodwill | 0.00 |
| Intangible assets | 378.19K |
| Property, plant and equipment | 1.81M |
| Total assets | 88.34M |
| Accounts payable | 2.68M |
| Short/Current long term debt | 28.30M |
| Total current liabilities | 5.73M |
| Total liabilities | 33.78M |
| Shareholder's equity | 54.56M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -36.48M |
| Capital expenditures (TTM) | 4.56M |
| Free cash flow (TTM) | -41.04M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -72.61% |
| Return on Assets | -44.85% |
| Return on Invested Capital | -48.07% |
| Cash Return on Invested Capital | -49.79% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 35.00 |
| Daily high | 35.90 |
| Daily low | 34.00 |
| Daily Volume | 19K |
| All-time high | 177.94 |
| 1y analyst estimate | 124.16 |
| Beta | 0.42 |
| EPS (TTM) | -2.64 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 25 Feb 2026 |
Downside potential
Loading...
Downside potential data
| FLUO.ST | S&P500 | |
| Current price drop from All-time high | -80.11% | -1.82% |
| Highest price drop | -82.52% | -56.47% |
| Date of highest drop | 5 Feb 2026 | 9 Mar 2009 |
| Avg drop from high | -51.74% | -10.84% |
| Avg time to new high | 44 days | 12 days |
| Max time to new high | 1281 days | 1805 days |
COMPANY DETAILS
Marketcap
578.77M
Marketcap category
Small-cap
Description
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer. The company was incorporated in 2018 and is based in Copenhagen, Denmark.
Employees
6
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
COPENHAGEN, DK / ACCESS Newswire / February 25, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO) hereby publishes its annual report for the fiscal year 2025. The annual report, including ...
February 25, 2026
COPENHAGEN, DK / ACCESS Newswire / February 25, 2026 / Fluoguide A/S ("FluoGuide" or the "Company")(STO:FLUO) today releases its results for the period 1 January 2025 - 31 December 2025. The Q4 report...
February 25, 2026
COPENHAGEN, DENMARK / ACCESS Newswire / February 20, 2026 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, a...
February 20, 2026
KØBENHAVN, DK / ACCESS Newswire / February 19, 2026 / FluoGuide A/S (STO:FLUO) will publish its Annual Report 2025 on Wednesday, 25 February 2026. Later that day, CEO Morten Albrechtsen and CFO Ole La...
February 19, 2026
KØBENHAVN, DK / ACCESS Newswire / January 21, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today ann...
January 21, 2026
KØBENHAVN, DK / ACCESS Newswire / November 27, 2025 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO) today releases its results for the period 1 January - 30 September 2025. The Q3 report is ...
November 27, 2025
KØBENHAVN, DK / ACCESS Newswire / November 25, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark, 25 November 2025 - FluoGuide A/S, a biotech company specializing in precision cancer surgery, anno...
November 25, 2025
KØBENHAVN, DK / ACCESS Newswire / November 24, 2025 /FluoGuide A/S (STO:FLUO)("FluoGuide" or the "Company" held an extraordinary general meeting on 24 November 2025. To the shareholders of FluoGuide A...
November 24, 2025
KØBENHAVN, DK / ACCESS Newswire / November 24, 2025 / FluoGuide A/S (STO:FLUO) - FluoGuide A/S will publish its Interim Report Q3 2025 on Thursday 27 November 2025. The following event will take place...
November 24, 2025
KØBENHAVN, DK / ACCESS Newswire / November 5, 2025 /FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces changes to both its c...
November 5, 2025
Next page